Correlating In Vitro Splice Switching Activity With Systemic In Vivo Delivery Using Novel ZEN-modified Oligonucleotides

• Published in: Molecular therapy. Nucleic acids 2014, Vol.3 (11), p.e212-e212, Article e212
• Main Authors: Hammond, Suzan M, McClorey, Graham, Nordin, Joel Z, Godfrey, Caroline, Stenler, Sofia, Lennox, Kim A, Smith, CI Edvard, Jacobi, Ashley M, Varela, Miguel A, Lee, Yi, Behlke, Mark A, Wood, Matthew J A, Andaloussi, Samir E L
• Format: Article
• Language: English
• Subjects: antisense oligonucleotides; Duchenne muscular dystrophy; Medicin och hälsovetenskap; Original; splice switching; ZEN modification
• ISSN: 2162-2531; 2162-2531
• DOI: 10.1038/mtna.2014.63

Splice switching oligonucleotides (SSOs) induce alternative splicing of pre-mRNA and typically employ chemical modifications to increase nuclease resistance and binding affinity to target pre-mRNA. Here we describe a new SSO non-base modifier (a naphthyl-azo group, “ZEN™”) to direct exon exclusion in mutant dystrophin pre-mRNA to generate functional dystrophin protein. The ZEN modifier is placed near the ends of a 2′-O-methyl (2′OMe) oligonucleotide, increasing melting temperature and potency over unmodified 2′OMe oligonucleotides. In cultured H2K cells, a ZEN-modified 2′OMe phosphorothioate (PS) oligonucleotide delivered by lipid transfection greatly enhanced dystrophin exon skipping over the same 2′OMePS SSO lacking ZEN. However, when tested using free gymnotic uptake in vitro and following systemic delivery in vivo in dystrophin deficient mdx mice, the same ZEN-modified SSO failed to enhance potency. Importantly, we show for the first time that in vivo activity of anionic SSOs is modelled in vitro only when using gymnotic delivery. ZEN is thus a novel modifier that enhances activity of SSOs in vitro but will require improved delivery methods before its in vivo clinical potential can be realized.